3,451 results on '"Terbuch, A."'
Search Results
202. Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia.
- Author
-
Tenuta, Marta, Pandozzi, Carla, Sciarra, Francesca, Campolo, Federica, Gelibter, Alain J., Sirgiovanni, Grazia, Cortesi, Enrico, Lenzi, Andrea, Isidori, Andrea M., Sbardella, Emilia, and Venneri, Mary Anna
- Subjects
LUNG cancer ,FLOW cytometry ,IMMUNE checkpoint inhibitors ,SCIENTIFIC observation ,CONFIDENCE intervals ,KILLER cells ,SARCOPENIA ,TUMOR classification ,DESCRIPTIVE statistics ,RESEARCH funding ,TUMOR markers ,BLOOD cell count ,LONGITUDINAL method - Abstract
Simple Summary: In this study, we provide a basal and longitudinal evaluation of immune cells in advanced non-small-cell lung cancer (NSCLC) patients undergoing PD-1 or PD-L1 blockade. We aimed to explore if any data could be predictive of better outcomes and long-term survival and to detect eventual connections among immune cell subsets and sarcopenia, another known risk factor for progression disease (PD). We found that natural killer (NK) cell basal levels are higher in patients with disease control (DC) compared to PD patients; higher NK cell basal levels predict a longer overall survival (OS); lower NK values represent a risk factor for PD; and after three months of immune check-point inhibitors (ICIs) treatment, NK cells (and the subclass CD56
bright ) significantly increase in DC patients. Interestingly, sarcopenic patients show lower NK cell values at basal levels. Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of tumors. Natural killer (NK) cells can play an important role in cancer immune surveillance. The aim of this prospective observational study was to analyze peripheral blood mononuclear cells (PBMCs) in patients with advanced non-small-cell lung cancer (NSCLC) receiving ICIs in order to identify predictive factors for better survival outcomes. Methods: Forty-seven stage IV NSCLC patients were enrolled. Patients underwent baseline (T0 ) and longitudinal (T1 ) evaluations after ICIs. Peripheral immune blood cell counts were analyzed using flow cytometry. Results: Basal levels of CD3− CD56+ NK cells were higher in patients with controlled disease (DC) compared to progression disease (PD) patients (127 cells/µL vs. 27.8 cells/µL, p < 0.001). Lower NK cell values were independent prognostic factors for shorter overall survival (OS) (HR 0.992; 95% CI 0.987–0.997, p < 0.001) and progression-free survival (PFS) (HR 0.988; 95% CI 0.981–0.994, p < 0.001). During the longitudinal evaluation, CD3− CD56+ NK cells (138.1 cells/µL vs. 127 cells/µL, p = 0.025) and CD56bright NK cells (27.4 cells/µL vs. 18.1 cells/µL, p = 0.034) significantly increased in the DC group. Finally, lower values of CD3− CD56+ NK cells (28.3 cells/µL vs. 114.6 cells/µL, p = 0.004) and CD56dim NK cells (13.2 cells/µL vs. 89.4 cells/µL, p < 0.001) were found in sarcopenic patients compared to patients without sarcopenia. Conclusions: Peripheral NK cells could represent a non-invasive and useful tool to predict ICI therapy response in NSCLC patients, and the association of low NK cell levels with sarcopenia deserves even more attention in clinical evaluation. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
203. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.
- Author
-
Castillo, Dani Ran, Jeon, Won Jin, Park, Daniel, Pham, Bryan, Yang, Chieh, Joung, Bowon, Moon, Jin Hyun, Lee, Jae, Chong, Esther G., Park, Kiwon, Reeves, Mark E., Duerksen-Hughes, Penelope, Mirshahidi, Hamid R., and Mirshahidi, Saied
- Subjects
PROGRAMMED cell death 1 receptors ,PROGRAMMED death-ligand 1 ,NON-small-cell lung carcinoma ,IMMUNE checkpoint inhibitors - Abstract
In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer (NSCLC), have advanced significantly, offering tailored treatment options for patients. However, individuals without targetable mutations pose a clinical challenge, as they may not respond to standard treatments like immune-checkpoint inhibitors (ICIs) and novel targeted therapies. While the mechanism of action of ICIs seems promising, the lack of a robust response limits their widespread use. Although the expression levels of programmed death ligand 1 (PD-L1) on tumor cells are used to predict ICI response, identifying new biomarkers, particularly those associated with the tumor microenvironment (TME), is crucial to address this unmet need. Recently, inflammatory cytokines such as interleukin-1 beta (IL-1β) have emerged as a key area of focus and hold significant potential implications for future clinical practice. Combinatorial approaches of IL-1β inhibitors and ICIs may provide a potential therapeutic modality for NSCLC patients without targetable mutations. Recent advancements in our understanding of the intricate relationship between inflammation and oncogenesis, particularly involving the IL-1β/PD-1/PD-L1 pathway, have shed light on their application in lung cancer development and clinical outcomes of patients. Targeting these pathways in cancers like NSCLC holds immense potential to revolutionize cancer treatment, particularly for patients lacking targetable genetic mutations. However, despite these promising prospects, there remain certain aspects of this pathway that require further investigation, particularly regarding treatment resistance. Therefore, the objective of this review is to delve into the role of IL-1β in NSCLC, its participation in inflammatory pathways, and its intricate crosstalk with the PD-1/PD-L1 pathway. Additionally, we aim to explore the potential of IL-1β as a therapeutic target for NSCLC treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
204. Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.
- Author
-
Fuentes-Antrás, Jesús, Martínez-Rodríguez, Ana, Guevara-Hoyer, Kissy, López-Cade, Igor, Lorca, Víctor, Pascual, Alejandro, de Luna, Alicia, Ramírez-Ruda, Carmen, Swindell, Jennifer, Flores, Paloma, Lluch, Ana, Cescon, David W., Pérez-Segura, Pedro, Ocaña, Alberto, Jones, Frederick, Moreno, Fernando, García-Barberán, Vanesa, and García-Sáenz, José Ángel
- Subjects
METASTATIC breast cancer ,AROMATASE inhibitors ,CANCER patients ,CIRCULATING tumor DNA ,SOMATIC mutation ,BREAST - Abstract
Endocrine-resistant, hormone receptor-positive, and HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) is largely governed by acquired mutations in the estrogen receptor, which promote ligand-independent activation, and by truncal alterations in the PI3K signaling pathway, with a broader range of gene alterations occurring with less prevalence. Circulating tumor DNA (ctDNA)-based technologies are progressively permeating the clinical setting. However, their utility for serial monitoring has been hindered by their significant costs, inter-technique variability, and real-world patient heterogeneity. We interrogated a longitudinal collection of 180 plasma samples from 75 HR+/HER2- mBC patients who progressed or relapsed after exposure to aromatase inhibitors and were subsequently treated with endocrine therapy (ET) by means of highly sensitive and affordable digital PCR and SafeSEQ sequencing. Baseline PIK3CA and TP53 mutations were prognostic of a shorter progression-free survival in our population. Mutant PIK3CA was prognostic in the subset of patients receiving fulvestrant monotherapy after progression to a CDK4/6 inhibitor (CDK4/6i)-containing regimen, and its suppression was predictive in a case of long-term benefit with alpelisib. Mutant ESR1 was prognostic in patients who did not receive concurrent CDK4/6i, an impact influenced by the variant allele frequency, and its early suppression was strongly predictive of efficacy and associated with long-term benefit in the whole cohort. Mutations in ESR1, TP53, and KRAS emerged as putative drivers of acquired resistance. These findings collectively contribute to the characterization of longitudinal ctDNA in real-world cases of HR+/HER2- mBC previously exposed to aromatase inhibitors and support ongoing studies either targeting actionable alterations or leveraging the ultra-sensitive tracking of ctDNA. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
205. Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling.
- Author
-
Jiaming Gao, Yunying Yao, Chenxuan Liu, Xi Xie, Donghe Li, Ping Liu, Zaiqi Wang, Baoyuan Zhang, and Ren, Ruibao
- Published
- 2023
- Full Text
- View/download PDF
206. The Adaptive Mechanisms and Checkpoint Responses to a Stressed DNA Replication Fork.
- Author
-
Saldanha, Joanne, Rageul, Julie, Patel, Jinal A., and Kim, Hyungjin
- Subjects
DNA replication ,SINGLE-stranded DNA ,DNA synthesis ,DNA repair ,DNA damage ,PSYCHOLOGICAL stress ,PROGRAMMED cell death 1 receptors ,CELL survival - Abstract
DNA replication is a tightly controlled process that ensures the faithful duplication of the genome. However, DNA damage arising from both endogenous and exogenous assaults gives rise to DNA replication stress associated with replication fork slowing or stalling. Therefore, protecting the stressed fork while prompting its recovery to complete DNA replication is critical for safeguarding genomic integrity and cell survival. Specifically, the plasticity of the replication fork in engaging distinct DNA damage tolerance mechanisms, including fork reversal, repriming, and translesion DNA synthesis, enables cells to overcome a variety of replication obstacles. Furthermore, stretches of single-stranded DNA generated upon fork stalling trigger the activation of the ATR kinase, which coordinates the cellular responses to replication stress by stabilizing the replication fork, promoting DNA repair, and controlling cell cycle and replication origin firing. Deregulation of the ATR checkpoint and aberrant levels of chronic replication stress is a common characteristic of cancer and a point of vulnerability being exploited in cancer therapy. Here, we discuss the various adaptive responses of a replication fork to replication stress and the roles of ATR signaling that bring fork stabilization mechanisms together. We also review how this knowledge is being harnessed for the development of checkpoint inhibitors to trigger the replication catastrophe of cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
207. Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer.
- Author
-
Martinis, Eleonora, Ricci, Carolina, Trevisan, Caterina, Tomadini, Gaia, and Tonon, Silvia
- Subjects
COLORECTAL cancer ,CANCER vaccines ,CANCER treatment ,B cells ,TUMOR antigens - Abstract
Colorectal cancer represents 10% of all new cancer cases each year and accounts for almost 10% of all cancer deaths. According to the WHO, by 2040 there will be a 60% increase in colorectal cancer cases. These data highlight the need to explore new therapeutic strategies. Classical interventions include surgical resection, chemotherapy and radiotherapy, which are invasive strategies that have many side effects on the patients and greatly affect their quality of life. A great advance in the treatment of this cancer type, as well as of all the others, could be the development of a vaccination strategy preventing the onset, the progression or the relapse of the pathology. In this review, we summarize the main vaccination strategies that are being studied for the treatment of colorectal cancer (CRC) and finally explore the possibility of using B-cells for the development of a new type of vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
208. DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy.
- Author
-
Obata, Honoka, Ogawa, Mikako, and Zalutsky, Michael R.
- Subjects
DNA repair ,DNA methyltransferases ,TRANSCRIPTION factors ,CANCER cells ,DRUG target ,NANOMEDICINE ,RADIOISOTOPES ,AUGER effect - Abstract
The present review aims to explore the potential targets/partners for future targeted radionuclide therapy (TRT) strategies, wherein cancer cells often are not killed effectively, despite receiving a high average tumor radiation dose. Here, we shall discuss the key factors in the cancer genome, especially those related to DNA damage response/repair and maintenance systems for escaping cell death in cancer cells. To overcome the current limitations of TRT effectiveness due to radiation/drug-tolerant cells and tumor heterogeneity, and to make TRT more effective, we propose that a promising strategy would be to target the DNA maintenance factors that are crucial for cancer survival. Considering their cancer-specific DNA damage response/repair ability and dysregulated transcription/epigenetic system, key factors such as PARP, ATM/ATR, amplified/overexpressed transcription factors, and DNA methyltransferases have the potential to be molecular targets for Auger electron therapy; moreover, their inhibition by non-radioactive molecules could be a partnering component for enhancing the therapeutic response of TRT. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
209. Emerging strategies for cancer therapy by ATR inhibitors.
- Author
-
Yano, Kimiyoshi and Shiotani, Bunsyo
- Abstract
DNA replication stress (RS) causes genomic instability and vulnerability in cancer cells. To counteract RS, cells have evolved various mechanisms involving the ATR kinase signaling pathway, which regulates origin firing, cell cycle checkpoints, and fork stabilization to secure the fidelity of replication. However, ATR signaling also alleviates RS to support cell survival by driving RS tolerance, thereby contributing to therapeutic resistance. Cancer cells harboring genetic mutations and other changes that disrupt normal DNA replication increase the risk of DNA damage and the levels of RS, conferring addiction to ATR activity for sustainable replication and susceptibility to therapeutic approaches using ATR inhibitors (ATRis). Therefore, clinical trials are currently being conducted to evaluate the efficacy of ATRis as monotherapies or in combination with other drugs and biomarkers. In this review, we discuss recent advances in the elucidation of the mechanisms by which ATR functions in the RS response and its therapeutic relevance when utilizing ATRis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
210. Design, synthesis, and anti‐breast cancer activity evaluation of endoperoxide‐type pyrido/pyrrolo[2,3‐d]pyrimidine derivatives.
- Author
-
Song, Yu‐Yang, Xia, Kai, Wu, Xiao‐Qiang, Zeng, Chang‐Guang, Tang, Shu‐Ai, Yuan, Yue, Gui, Yu‐Ting, Zhang, Xiao‐Han, and Zhong, Hang
- Subjects
PYRIMIDINES ,CYCLIN-dependent kinases ,PYRIMIDINE derivatives ,NUCLEAR magnetic resonance ,MASS spectrometry ,INFRARED spectroscopy - Abstract
Cyclin‐dependent kinase 4 and 6 (CDK 4/6) overactivation in breast cancer cells has given birth to the successful development of CDK 4/6 inhibitors. Based on the intrinsic relationship of CDK 4/6 and cyclin D, we designed and synthesized a series of endoperoxide‐type pyrido/pyrrolo[2,3‐d]pyrimidine derivatives via extracting active fragments from canonical CDK 4/6 inhibitors and endoperoxide‐type natural products such as artemisinin and plakortin. Eleven novel endoperoxide‐type hybrids were synthesized and characterized by mass spectrometry (MS), high resolution mass spectrometry (HRMS), infrared spectroscopy (IR), hydrogen‐1 nuclear magnetic resonance (1H NMR), and carbon‐13 nuclear magnetic resonance (13C NMR) data. Antiproliferative activities and CDK 4/6 inhibitory effects of target compounds were evaluated via T47D, MDA‐MB‐436 breast cancer cell lines, and CDK6/cyclin D3 kinase respectively. The results showed that S1 and Y7 were the most potent compounds against CDK6/cyclin D3 kinase, with Half maximal inhibitory concentration (IC50) values of 0.126 ± 0.022 and 0.109 ± 0.007 μM respectively, they were about a half or third as potent as positive control palbociclib (0.045 μM). The antiproliferative effects of S2 were close to positive controls palbociclib and ribociclib, with Growth inhibitory dose 50% (GI50) values of 8.42 ± 0.93 and 18.74 ± 1.78 μM towards T47D cells and MDA‐MB‐436 cells respectively. Finally, antiproliferative activities against MCF‐10A cells indicated that our newly synthesized compounds were harmless to normal human mammary epithelial cells. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
211. More help than harm: surgery for metastatic spinal cord compression is associated with more favorable overall survival within a propensity score analysis.
- Author
-
Leitner, Lukas, Bratschitsch, Gerhard, Kostwein, Anna, Sadoghi, Patrick, Smolle, Maria, Leithner, Andreas, and Posch, Florian
- Subjects
SPINAL cord compression ,SPINAL cord surgery ,OVERALL survival ,SPINAL surgery ,SURGICAL indications ,SURGICAL decompression - Abstract
Purpose: Indication for surgical decompression in metastatic spinal cord compression (MSCC) is often based on prognostic scores such as the modified Bauer score (mBs), with favorable prognosis suggestive of surgery and poor prognosis of non-surgical management. This study aimed to clarify if (1) surgery may directly affect overall survival (OS) aside from short-term neurologic outcome, (2) explore whether selected patient subgroups with poor mBs might still benefit from surgery, and (3) gauge putative adverse effects of surgery on short-term oncologic outcomes. Methods: Single-center propensity score analyses with inverse-probability-of-treatment-weights (IPTW) of OS and short-term neurologic outcomes in MSCC patients treated with or without surgery between 2007 and 2020. Results: Among 398 patients with MSCC, 194 (49%) underwent surgery. During a median follow-up of 5.8 years, 355 patients (89%) died. MBs was the most important predictor for spine surgery (p < 0.0001) and the strongest predictor of favorable OS (p < 0.0001). Surgery was associated with improved OS after accounting for selection bias with the IPTW method (p = 0.021) and emerged as the strongest determinant of short-term neurological improvement (p < 0.0001). Exploratory analyses delineated a subgroup of patients with an mBs of 1 point who still benefited from surgery, and surgery did not result in a higher risk of short-term oncologic disease progression. Conclusion: This propensity score analysis corroborates the concept that spine surgery for MSCC associates with more favorable neurological and OS outcomes. Selected patients with poor prognosis might also benefit from surgery, suggesting that even those with low mBs may be considered for this intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
212. Pancreatic Cancer: BRCA Targeted Therapy and Beyond.
- Author
-
Keane, Fergus, O'Connor, Catherine A., Park, Wungki, Seufferlein, Thomas, and O'Reilly, Eileen M.
- Subjects
THERAPEUTIC use of antineoplastic agents ,PANCREATIC tumors ,ADENOCARCINOMA ,GENETIC mutation ,BRCA genes ,CANCER chemotherapy ,DRUG resistance ,DUCTAL carcinoma ,PLATINUM ,TREATMENT effectiveness ,GENOMES ,DNA damage - Abstract
Simple Summary: Pancreatic cancer is associated with poor outcomes for several reasons, including diagnosis at an advanced stage, the absence of effective screening for the diagnosis, and resistance to treatments. Pancreatic cancers associated with BRCA1/2 mutations have emerged as a distinct subgroup with sensitivity to other treatments and, in some cases, durable responses. Furthermore, beyond BRCA1/2 mutations, there is increasing recognition that other gene mutations may behave in a similar manner. The focus of this review is to discuss recent developments in the management of BRCA-associated pancreatic cancer, emerging therapeutic strategies, and future directions for this subgroup of patients. Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related death in the US by 2030, despite accounting for only 5% of all cancer diagnoses. Germline gBRCA1/2-mutated PDAC represents a key subgroup with a favorable prognosis, due at least in part to additional approved and guideline-endorsed therapeutic options compared with an unselected PDAC cohort. The relatively recent incorporation of PARP inhibition into the treatment paradigm for such patients has resulted in renewed optimism for a biomarker-based approach to the management of this disease. However, gBRCA1/2 represents a small subgroup of patients with PDAC, and efforts to extend the indication for PARPi beyond BRCA1/2 mutations to patients with PDAC and other genomic alterations associated with deficient DNA damage repair (DDR) are ongoing, with several clinical trials underway. In addition, despite an array of approved therapeutic options for patients with BRCA1/2-associated PDAC, both primary and acquired resistance to platinum-based chemotherapies and PARPi presents a significant challenge in improving long-term outcomes. Herein, we review the current treatment landscape of PDAC for patients with BRCA1/2 and other DDR gene mutations, experimental approaches under investigation or in development, and future directions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
213. Application of Metal-Based Nanomaterials in In Vitro Diagnosis of Tumor Markers: Summary and Prospect.
- Author
-
Yang, Xiaobo, Zhang, Shaodian, and Lin, Nong
- Subjects
TUMOR diagnosis ,TUMOR markers ,LITERATURE reviews ,NANOSTRUCTURED materials ,MEDICAL screening - Abstract
Cancer, which presents with high incidence and mortality rates, has become a significant health threat worldwide. However, there is currently no effective solution for rapid screening and high-quality treatment of early-stage cancer patients. Metal-based nanoparticles (MNPs), as a new type of compound with stable properties, convenient synthesis, high efficiency, and few adverse reactions, have become highly competitive tools for early cancer diagnosis. Nevertheless, challenges such as the difference between the microenvironment of detected markers and the real-life body fluids remain in achieving widespread clinical application of MNPs. This review provides a comprehensive review of the research progress made in the field of in vitro cancer diagnosis using metal-based nanoparticles. By delving into the characteristics and advantages of these materials, this paper aims to inspire and guide researchers towards fully exploiting the potential of metal-based nanoparticles in the early diagnosis and treatment of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
214. APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR/Chk1 inhibitors.
- Author
-
Zong, Chunyan, Zhang, Zhe, Gao, Li, He, Jie, Wang, Yiran, Li, Qian, Liu, Xiaoting, Yang, Jie, Chen, Di, Huang, Rui, Zheng, Guopei, Jin, Xiaoliang, Wei, Wu, Jia, Renbing, and Shen, Jianfeng
- Published
- 2023
- Full Text
- View/download PDF
215. Imaging Recommendations for Diagnosis, Staging and Management of Treatment-Related Complications in Cancer.
- Author
-
Mukhopadhyay, Sumit, Sen, Saugata, Ghosh, Priya, Gehani, Anisha, Patra, Anurima, Chandra, Aditi, Chatterjee, Argha, Lingegowda, Dayananda, Gupta, Bharat, Gupta, Meenu, Venugopal, Prakash, Chakraborty, Amrita, Pathak, Ketul K., Mishra, Pradipta Kumar, and Khoda, Jeevitesh
- Subjects
CANCER complications ,DIAGNOSIS ,MEDICAL care ,INDIVIDUALIZED medicine ,PHYSICIANS ,RADIOTHERAPY - Abstract
Precision medicine is becoming increasingly common in oncology, with treatments tailored to individual patients and cancer. By integrating these underlying concepts of health care, chemotherapy and radiotherapy can be tailored to improve safety and efficacy. On the other hand, oncology treatment regimens may result in local and systemic changes and complications depending on the type of treatment. For the proper and prompt management of cancer patients, it is essential to interpret this posttreatment imaging correctly. This article aims at guiding treating physicians to be able to distinguish complications from expected posttreatment changes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
216. EAPC2023 Abstract Book.
- Subjects
CONFERENCES & conventions ,PALLIATIVE treatment - Abstract
The article focuses on the 18 European Association of Preventive Cardiology (EAPC) World Congress in Rotterdam, which marks the return to an in-person event after years of virtual congresses. It mentions the congress aims to promote equity and diversity in palliative care, addressing health inequities and exploring the role of diversity in improving access and outcomes.
- Published
- 2023
- Full Text
- View/download PDF
217. Prospective role of 3βHSD1 in prostate cancer precision medicine.
- Author
-
Zhuang, Qian, Huang, Shengsong, and Li, Zhenfei
- Published
- 2023
- Full Text
- View/download PDF
218. MiRNA biomarkers in cancers of the male reproductive system: Are we approaching clinical application?
- Author
-
Constâncio, Vera, Tavares, Nuno Tiago, Henrique, Rui, Jerónimo, Carmen, and Lobo, João
- Subjects
MALE reproductive organs ,TUMOR markers ,MICRORNA ,CLINICAL medicine ,TESTIS tumors ,PROSTATE cancer - Abstract
Background: Specific cancer types face specific clinical management challenges. Owing to their stability, robustness and fast, easy and cost‐effective detection, microRNAs (miRNAs) are attractive candidate biomarkers to the clinic. Objectives: Based on a comprehensive review of the relevant literature in the field, we explore the potential of miRNAs as biomarkers to answer relevant clinical dilemmas inherent to cancers of the male reproductive tract (prostate [PCa], testis [TGCTs] and penis [PeCa]) and identify some of the challenges/limitations hampering their widely application. Results and discussion: We conclude that the use of miRNAs as biomarkers is at different stages for these distinct cancer types. While for TGCTs, miRNA‐371a‐3p is universally accepted to fill in important clinicals gaps and is moving fast towards clinical implementation, for PCa almost no overlap of miRNAs exists between studies, denoting the absence of a consistent miRNA biomarker, and for PeCa the field of miRNAs has just recently started, with only a few studies attempting to explore their clinical usefulness. Conclusion: Technological advances influencing miRNA detection and quantification will be instrumental to continue to move forward with implementation of miRNAs in the clinic as biomarkers for non‐invasive diagnosis, risk stratification, treatment monitoring and follow‐up. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
219. Differences in DNA damage repair gene mutations between left‐ and right‐sided colorectal cancer.
- Author
-
Huang, Wei, Li, Wenliang, Xu, Ning, Li, Hui, Zhang, Zihan, Zhang, Xiaolong, He, Tingting, Yao, Jicheng, Xu, Mian, He, Qingqing, Guo, Lijie, and Zhang, Sen
- Subjects
DNA repair ,COLORECTAL cancer ,DNA damage ,GENETIC mutation ,PROPORTIONAL hazards models - Abstract
Background: Colorectal cancer (CRC) is the third leading cause of cancer‐related deaths worldwide. Studies have shown that the DNA damage response (DDR) mutation is strongly associated with microsatellite instability (MSI) status and is an indication for patients with CRCs receiving immune checkpoint inhibitor (ICI) treatment. However, DDR mutation in microsatellite stable (MSS) CRC remains unclear. Methods: In this study, Fisher's exact test, Student'st‐test, Wilcoxon rank‐sum test and Cox proportional hazards regression model were performed, and a p value of < 0.05 was considered statistically significant. Results: The most common gene alterations were APC (77%), TP53 (73%), KRAS (48%), and PIK3CA (25%). The mutationfrequency of APC and TP53 in left‐sided CRC was significantly higher than that for right‐sided CRC, while the mutation frequency of PIK3CA, ACVR2A, FAT4, and RNF43 in right‐sided CRC was significantly higher than that for left‐sided CRC. DDR mutations occurred in100% of MSI CRCs and in 83.77% of MSS CRCs, with the most frequently mutated DDR genes being ARID1A (7.5%), ATM (5.7%,) and BRCA2 (2.6%). When right‐ and left‐sided CRCs were compared, no significant difference was observed for DDR genes and pathways. A survival analysis indicated that the DDR mutation was not associated with overall survival (OS) in MSS CRCs, while left‐sided patients with homologous recombination repair (HRR) pathway mutations had a significantly prolonged OS compared with right‐sided CRCs. Conclusions: Here, we found that stage and grade were statistically significant independent prognostic factors in the left‐sided CRC and the right‐sided CRC, recommending treatment for these patients stratified by stage. For the future, utilizing DDR gene defects for expanding treatment options and improving prognosis is an issue worth exploring. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
220. FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.
- Author
-
Tarin, Malcy, Némati, Fariba, Decaudin, Didier, Canbezdi, Christine, Marande, Benjamin, Silva, Lisseth, Derrien, Héloïse, Jochemsen, Aart G., Gardrat, Sophie, Piperno-Neumann, Sophie, Rodrigues, Manuel, Mariani, Pascale, Cassoux, Nathalie, Stern, Marc-Henri, Roman-Roman, Sergio, and Alsafadi, Samar
- Subjects
IN vitro studies ,IN vivo studies ,XENOGRAFTS ,GENETIC mutation ,MELANOMA ,PROTEIN kinase inhibitors ,ANIMAL experimentation ,UVEA cancer ,METASTASIS ,ANTINEOPLASTIC agents ,APOPTOSIS ,PROTEIN-tyrosine kinase inhibitors ,CELL survival ,DRUG synergism ,RESEARCH funding ,CELL lines ,MICE ,PHARMACODYNAMICS - Abstract
Simple Summary: Uveal Melanoma (UM) is a rare and malignant intraocular tumor with dismal prognosis. Despite efficient control of the primary tumor by radiation or surgery, up to 50% of patients subsequently develop metastases, mainly in the liver. The treatment of UM metastases is challenging and the patient survival is very poor. Today, most of the tested treatments including inhibitors of protein kinase C (PKC), mitogen-activated protein kinase (MEK) or immune checkpoint blockade have been largely ineffective in patients with metastatic UM. Given that single-agent targeted therapies often activate compensatory mechanisms, combination strategies are relevant to evaluate in UM in preclinical and clinical settings. Our study confirms the previously described synergy of the dual inhibition of focal adhesion kinase (FAK) and MEK, and identifies a novel combination of drugs (FAK and PKC inhibitors) as a promising strategy for therapeutic intervention in metastatic UM. Uveal Melanoma (UM) is a rare and malignant intraocular tumor with dismal prognosis. Even if radiation or surgery permit an efficient control of the primary tumor, up to 50% of patients subsequently develop metastases, mainly in the liver. The treatment of UM metastases is challenging and the patient survival is very poor. The most recurrent event in UM is the activation of Gαq signaling induced by mutations in GNAQ/11. These mutations activate downstream effectors including protein kinase C (PKC) and mitogen-activated protein kinases (MAPK). Clinical trials with inhibitors of these targets have not demonstrated a survival benefit for patients with UM metastasis. Recently, it has been shown that GNAQ promotes YAP activation through the focal adhesion kinase (FAK). Pharmacological inhibition of MEK and FAK showed remarkable synergistic growth-inhibitory effects in UM both in vitro and in vivo. In this study, we have evaluated the synergy of the FAK inhibitor with a series of inhibitors targeting recognized UM deregulated pathways in a panel of cell lines. The combined inhibition of FAK and MEK or PKC had highly synergistic effects by reducing cell viability and inducing apoptosis. Furthermore, we demonstrated that these combinations exert a remarkable in vivo activity in UM patient-derived xenografts. Our study confirms the previously described synergy of the dual inhibition of FAK and MEK and identifies a novel combination of drugs (FAK and PKC inhibitors) as a promising strategy for therapeutic intervention in metastatic UM. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
221. The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage.
- Author
-
Noce, Annalisa, Marrone, Giulia, Di Lauro, Manuela, Mitterhofer, Anna Paola, Ceravolo, Maria Josè, Di Daniele, Nicola, Manenti, Guglielmo, and De Lorenzo, Antonino
- Subjects
ACUTE kidney failure prevention ,NEPHROTOXICOLOGY ,CHRONIC kidney failure ,GLOMERULAR filtration rate ,CANCER chemotherapy ,KIDNEY failure ,HYDROTHERAPY ,CANCER patients ,HEMATOPOIETIC stem cell transplantation ,DISEASE risk factors - Abstract
Simple Summary: The onco-nephrology field: the interaction between cancer and kidney disease emphasizes the nephrology–oncology connection. This narrative review focuses on several aspects of this association. First of all, the availability of more effective chemotherapeutic agents, including stem cell therapies and biological drugs, has enhanced the survival of cancer patients. These therapeutic advances ameliorate the outcomes of cancer patients; nevertheless, they could induce secondary effects on renal function. As a consequence, some cancer survivors develop chronic kidney disease (CKD). On the other hand, the coexistence of CKD with cancer reduces the likelihood that cancer patients receive either the optimal anticancer therapy or the supportive care. Nephrologists should be aware of it, starting from an early cancer diagnosis; thus, it is important to set up nephroprotective supportive strategies to avoid the onset of acute kidney injury or the CKD worsening. In recent years, the onco-nephrology field has acquired a relevant role in internal medicine due to the growing number of cases of renal dysfunction that have been observed in cancer patients. This clinical complication can be induced by the tumor itself (for example, due to obstructive phenomena affecting the excretory tract or by neoplastic dissemination) or by chemotherapy, as it is potentially nephrotoxic. Kidney damage can manifest as acute kidney injury or represent a worsening of pre-existing chronic kidney disease. In cancer patients, physicians should try to set preventive strategies to safeguard the renal function, avoiding the concomitant use of nephrotoxic drugs, personalizing the dose of chemotherapy according to the glomerular filtration rate (GFR) and using an appropriate hydration therapy in combination with nephroprotective compounds. To prevent renal dysfunction, a new possible tool useful in the field of onco-nephrology would be the development of a personalized algorithm for the patient based on body composition parameters, gender, nutritional status, GFR and genetic polymorphisms. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
222. Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
- Author
-
Li, Yinuo, Wang, Xiangyu, Hou, Xin, and Ma, Xiangyi
- Subjects
DNA repair ,ENDOMETRIAL cancer ,DNA damage ,IMMUNE checkpoint inhibitors ,IMMUNE response - Abstract
Endometrial cancer (EC) is increasingly undermining female health worldwide, with poor survival rates for advanced or recurrent/metastatic diseases. The application of immune checkpoint inhibitors (ICIs) has opened a window of opportunity for patients with first-line therapy failure. However, there is a subset of patients with endometrial cancer who remain insensitive to immunotherapy alone. Therefore, it is necessary to develop new therapeutic agents and further explore reliable combinational strategies to optimize the efficacy of immunotherapy. DNA damage repair (DDR) inhibitors as novel targeted drugs are able to generate genomic toxicity and induce cell death in solid tumors, including EC. Recently, growing evidence has demonstrated the DDR pathway modulates innate and adaptive immunity in tumors. In this review, we concentrate on the exploration of the intrinsic correlation between DDR pathways, especially the ATM-CHK2-P53 pathway and the ATR-CHK1-WEE1 pathway, and oncologic immune response, as well as the feasibility of adding DDR inhibitors to ICIs for the treatment of patients with advanced or recurrent/metastatic EC. We hope that this review will offer some beneficial references to the investigation of immunotherapy and provide a reasonable basis for "double-checkpoint inhibition" in EC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
223. The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients.
- Author
-
Baz, M., Gondran-Teiller, V., Bressac, B., Cabaret, O., Fievet, A., Dimaria, M., Goldbarg, V., Colas, C., Bonnet-Dupeyron, M. N., Tinat, J., Lebrun, M., Mari, V., Limacher, J. M., Corsini, C., Ginglinger, E., Saurin, J. C., Brahimi, A., Rouzier, C., Giraud, S., and Schuster, H.
- Subjects
PANCREATIC cancer ,CANCER patients ,GERM cells ,BRCA genes ,NUCLEOTIDE sequencing - Abstract
Germline DNA alterations affecting homologous recombination pathway genes have been associated with pancreatic cancer (PC) risk. BRCA2 is the most studied gene and affects the management of PC patients and their families. Even though recent reports have suggested a similar role of germline ATM pathogenic variants (PV) in familial PC, there is still a disagreement between experts on how it could affect patient management given the lack of proper PC risk estimates. We retrospectively analyzed the germline data of 257 PC patients among whom nearly 50% were sporadic cases. We showed similar frequencies of BRCA2 (4.9%) and ATM (4.4%) PV or likely pathogenic variants, which were not related to familial history. Based on our findings and that of the literature, we suggest including ATM gene among the panel of genes analyzed in PC patients pending the publication of prospective studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
224. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
- Author
-
Liu, Chaofan, Wang, Xi, Qin, Wan, Tu, Jingyao, Li, Chunya, Zhao, Weiheng, Ma, Li, Liu, Bo, Qiu, Hong, and Yuan, Xianglin
- Published
- 2023
- Full Text
- View/download PDF
225. Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer.
- Author
-
Bekric, Dino, Neureiter, Daniel, Ablinger, Celina, Dobias, Heidemarie, Beyreis, Marlena, Ritter, Markus, Jakab, Martin, Bischof, Johannes, Koller, Ulrich, Kiesslich, Tobias, and Mayr, Christian
- Subjects
IN vitro studies ,BILE duct tumors ,GENETIC mutation ,NUCLEAR proteins ,ANTINEOPLASTIC agents ,TREATMENT effectiveness ,CELL survival ,GENE expression ,RESEARCH funding ,TUMOR suppressor genes ,CELL lines ,EPIGENOMICS ,PHARMACODYNAMICS - Abstract
Simple Summary: Treating biliary tract cancer (BTC) successfully remains to be a difficult task. Standard therapeutic options encompass surgery, radiation and chemotherapy, but the median survival has not improved beyond one year. The reasons for this might be diagnosis at an already late stage and resistance towards current therapy. Therefore, novel strategies to combat this gastrointestinal disease need to be investigated. One alternative option may be to inhibit the enhancer of Zeste homolog 2 (EZH2), a histone-lysine-N-methyltransferase that was already shown to play a role in oncogenesis in BTC. Tazemetostat, an FDA-approved EZH2-inhibitor, seems to harbor promising anti-cancer properties in various tumor types. Therefore, in this study, we aim to investigate for the first time if tazemetostat might be a potential novel therapeutic strategy in biliary tract cancer. Biliary tract cancer (BTC) is a gastrointestinal malignancy associated with a poor survival rate. Current therapies encompass palliative and chemotherapeutic treatment as well as radiation therapy, which results in a median survival of only one year due to standard therapeutic ineffectiveness or resistance. Tazemetostat is an FDA-approved inhibitor of enhancer of Zeste homolog 2 (EZH2), a methyltransferase involved in BTC tumorigenesis via trimethylation of histone 3 at lysine 27 (H3K27me3), an epigenetic mark associated with silencing of tumor suppressor genes. Up to now, there are no data available regarding tazemetostat as a possible treatment option against BTC. Therefore, the aim of our study is a first-time investigation of tazemetostat as a potential anti-BTC substance in vitro. In this study, we demonstrate that tazemetostat affects cell viability and the clonogenic growth of BTC cells in a cell line-dependent manner. Furthermore, we found a strong epigenetic effect at low concentrations of tazemetostat, which was independent of the cytotoxic effect. We also observed in one BTC cell line that tazemetostat increases the mRNA levels and protein expression of the tumor suppressor gene Fructose-1,6-bisphosphatase 1 (FBP1). Interestingly, the observed cytotoxic and epigenetic effects were independent of the mutation status of EZH2. To conclude, our study shows that tazemetostat is a potential anti-tumorigenic substance in BTC with a strong epigenetic effect. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
226. Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review.
- Author
-
Robinson, Matthew D., Livesey, Daniel, Hubner, Richard A., Valle, Juan W., and McNamara, Mairéad G.
- Abstract
Neuroendocrine neoplasms (NENs) are rare malignancies arising most commonly in the gastrointestinal and bronchopulmonary systems. Neuroendocrine carcinomas (NECs) are a subgroup of NENs characterised by aggressive tumour biology, poor differentiation and dismal prognosis. Most NEC primary lesions arise in the pulmonary system. However, a small proportion arise outside of the lung and are termed extrapulmonary (EP)-, poorly differentiated (PD)-NECs. Patients with local or locoregional disease may benefit from surgical excision; however, this is often not an option, due to late presentation. To date, treatment has mirrored that of small-cell lung cancer, with platinum–etoposide forming the basis of first-line treatment. There is a lack of consensus in relation to the most effective second-line treatment option. Low incidence, an absence of representative preclinical models and a lack of understanding of the tumour microenvironment all present challenges to drug development in this disease group. However, progress made in elucidating the mutational landscape of EP-PD-NEC and the observations made in several clinical trials are paving the way towards improving outcomes for these patients. The optimisation and strategic delivery of chemotherapeutic interventions according to tumour characteristics and the utilisation of targeted and immune therapies in clinical studies have yielded mixed results. Targeted therapies that complement specific genetic aberrations are under investigation, including AURKA inhibitors in those with MYCN amplifications, BRAF inhibitors in those with BRAFV600E mutations and EGFR suppression, and Ataxia Telangiectasia and Rad3-related inhibitors in patients with ATM mutations. Immune checkpoint inhibitors (ICIs) have conferred promising results in several clinical trials, particularly with dual ICIs and in combination with targeted therapy or chemotherapy. However, further prospective investigations are required to elucidate the impact of programmed cell death ligand 1 expression, tumour mutational burden and microsatellite instability on response. This review aims to explore the most recent developments in the treatment of EP-PD-NEC and contribute towards the requirement for clinical guidance founded on prospective evidence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
227. Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.
- Author
-
Sundararajan, Vignesh, Tan, Tuan Zea, Lim, Diana, Peng, Yanfen, Wengner, Antje Margret, Ngoi, Natalie Yan Li, Jeyasekharan, Anand D, and Tan, David Shao Peng
- Subjects
CHECKPOINT kinase 1 ,DNA repair ,GENE expression profiling ,BIOMARKERS ,CANCER cell proliferation - Abstract
Excessive genomic instability coupled with abnormalities in DNA repair pathways induces high levels of 'replication stress' when cancer cells propagate. Rather than hampering cancer cell proliferation, novel treatment strategies are turning their attention towards targeting cell cycle checkpoint kinases (such as ATR, CHK1, WEE1, and others) along the DNA damage response and replicative stress response pathways, thereby allowing unrepaired DNA damage to be carried forward towards mitotic catastrophe and apoptosis. The selective ATR kinase inhibitor elimusertib (BAY 1895344) has demonstrated preclinical and clinical monotherapy activity; however, reliable predictive biomarkers of treatment benefit are still lacking. In this study, using gene expression profiling of 24 cell lines from different cancer types and in a panel of ovarian cancer cell lines, we found that nuclear‐specific enrichment of checkpoint kinase 1 (CHK1) correlated with increased sensitivity to elimusertib. Using an advanced multispectral imaging system in subsequent cell line‐derived xenograft specimens, we showed a trend between nuclear phosphorylated CHK1 (pCHK1) staining and increased sensitivity to the ATR inhibitor elimusertib, indicating the potential value of pCHK1 expression as a predictive biomarker of ATR inhibitor sensitivity. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
228. Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages.
- Author
-
Cano Garcia, Cristina, Barletta, Francesco, Incesu, Reha-Baris, Piccinelli, Mattia Luca, Tappero, Stefano, Panunzio, Andrea, Tian, Zhe, Saad, Fred, Shariat, Shahrokh F., Antonelli, Alessandro, Terrone, Carlo, De Cobelli, Ottavio, Graefen, Markus, Tilki, Derya, Briganti, Alberto, Wenzel, Mike, Banek, Severine, Kluth, Luis A., Chun, Felix K. H., and Karakiewicz, Pierre I.
- Subjects
GERMINOMA ,CAUSES of death ,CANCER cells ,REGRESSION analysis ,TERATOMA ,CANCER patients ,TUMOR classification ,RISK assessment ,TESTIS tumors ,KAPLAN-Meier estimator ,DESCRIPTIVE statistics ,OVERALL survival - Abstract
Simple Summary: Previous analyses from referral centers of testicular cancer investigated the prognostic impact of presence of teratoma components in advanced testicular primary tumor specimens and observed conflicting results. However, data investigating pure teratoma in primary tumor specimens is limited and the prognostic impact is uncertain. To address this void, we tested for overall survival differences and subsequently, differences in cancer-specific and other-cause mortality in pure teratoma vs. mixed germ cell tumor patients. We aimed to test for survival differences between testicular pure teratoma vs. mixed germ cell tumor (GCT) patients in a stage-specific fashion. Pure teratoma and mixed GCT in primary tumor specimens were identified within the Surveillance, Epidemiology, and End Results database (2004–2019). Kaplan–Meier curves depicted five-year overall survival (OS) and subsequently, cumulative incidence plots depicted cancer-specific mortality (CSM) and other-cause mortality (OCM) in a stage-specific fashion. Multivariable competing risks regression (CRR) models were used. Of 9049 patients, 299 (3%) had pure teratoma. In stage I, II and III, five-year OS rates differed between pure teratoma and mixed GCT (stage I: 91.6 vs. 97.2%, p < 0.001; stage II: 100 vs. 95.9%, p < 0.001; stage III: 66.8 vs. 77.8%, p = 0.021). In stage I, survival differences originated from higher OCM (6.4 vs. 1.2%; p < 0.001). Conversely in stage III, survival differences originated from higher CSM (29.4 vs. 19.0%; p = 0.03). In multivariable CRR models, pure teratoma was associated with higher OCM in stage I (Hazard Ratio (HR): 4.83; p < 0.01). Conversely, in stage III, in multivariable CRR models, pure teratoma was associated with higher CSM (HR: 1.92; p = 0.04). In pure teratoma, survival disadvantage in stage I patients relates to OCM. Survival disadvantage in stage III pure teratoma originates from higher CSM. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
229. Annual table of contents: Geomechanics and Tunneling 2022.
- Subjects
TUNNEL design & construction - Published
- 2023
- Full Text
- View/download PDF
230. The first comprehensive genomic characterization of rectal squamous cell carcinoma.
- Author
-
Astaras, Christoforos, De Vito, Claudio, Chaskar, Prasad, Bornand, Aurelie, Khanfir, Kaouthar, Sciarra, Amedeo, Letovanec, Igor, Corro, Claudia, Dietrich, Pierre-Yves, Tsantoulis, Petros, and Koessler, Thibaud
- Subjects
SQUAMOUS cell carcinoma ,ANAL cancer ,HUMAN papillomavirus ,GENOMICS ,RECTAL cancer ,NUCLEOTIDE sequencing - Abstract
Background: Rectal cancers represent 35% of colorectal cancers; 90% are adenocarcinomas, while squamous cell carcinoma accounts for 0.3% of them. Given its rarity, little is known concerning its pathogenesis, molecular profile and therapeutic management. The current treatment trend is to treat rectal squamous cell carcinoma by analogy to anal squamous cell carcinoma with definitive chemo-radiotherapy, setting aside surgery in case of local recurrence. Methods: We performed an in-depth genomic analysis (next-generation sequencing, copy number variation, and human papilloma virus characterization) on 10 rectal squamous cell carcinoma samples and compared them in silico to those of anal squamous cell carcinoma and rectal adenocarcinoma. Results: Rectal squamous cell carcinoma shows 100% HPV positivity. It has a mutational (PIK3CA, PTEN, TP53, ATM, BCL6, SOX2) and copy number variation profile (3p, 10p, 10q, 16q deletion and 1q, 3q, 5p, 8q, 20p gain) similar to anal squamous cell carcinoma. PI3K/Akt/mTOR is the most commonly affected signaling pathway similarly to anal squamous cell carcinoma. Most commonly gained or lost genes seen in rectal adenocarcinoma (FLT3, CDX2, GNAS, BCL2, SMAD4, MALT1) are not found in rectal squamous cell carcinoma. Conclusion: This study presents the first comprehensive genomic characterization of rectal squamous cell carcinoma. We confirm the existence of this rare histology and its molecular similarity with anal squamous cell carcinoma. This molecular proximity confirms the adequacy of therapeutic management based on histology and not localization, suggesting that rectal squamous cell carcinoma should be treated like anal squamous cell carcinoma and not as a rectal adenocarcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
231. MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors.
- Author
-
Schönberger, Stefan, Mohseni, Mahsa Mir, Ellinger, Jörg, Tran, Giao Vu Quynh, Becker, Martina, Claviez, Alexander, Classen, Carl-Friedrich, Hermes, Barbara, Driever, Pablo Hernáiz, Jorch, Norbert, Lauten, Melchior, Mehlitz, Marcus, Schäfer, Niklas, Scheer-Preiss, Johanna, Schneider, Dominik T., Troeger, Anja, Calaminus, Gabriele, and Dilloo, Dagmar
- Subjects
CEREBROSPINAL fluid ,GERM cell tumors ,GERMINOMA - Abstract
Purpose: Intracranial germ cell tumors (iGCT) comprise germinoma and non-germinoma. Their diagnosis predominantly relies on biopsy as only one-fifth of patients present with elevated biomarkers (AFP/ß-HCG) in serum or cerebrospinal fluid (CSF). MicroRNAs (miR/miRNA) have emerged as non-invasive biomarkers in extracranial GCT and may potentially facilitate non-invasive diagnosis in iGCT. Methods: We analyzed eight miRNAs in serum and CSF from the miR-371~373- and miR-302/367-clusters and four miRNAs differentially expressed in iGCT tissue (miR-142-5p/miR-146a-5p/miR-335-5p/miR-654-3p) from eight iGCT patients (age 10–33 years) and 12 control subjects by pre-amplified RT-qPCR. MiR-30b-5p (serum) and miR-204-5p (CSF) acted as reference genes. ΔC
t -values were expressed as 2 - Δ Δ C t after standardization against controls. Results: Between iGCT and control patients' serum ΔCt -values of miR-371a-3p (p = 0.0159), miR-372-3p (p= 0.0095, miR-367 (p = 0.0190), miR-302a (p = 0.0381) and miR-302d-3p (p = 0.0159) differed significantly. Discriminatory pattern in CSF was similar to serum as miR-371a (p = 0.0286), miR-372-3p (p = 0.0028), miR-367-3p (p = 0.0167) and miR-302d-3p (p = 0.0061) distinguished between patients and controls. Abundant 2 - Δ Δ C t levels of each of these miRNAs were found across all serum and CSF samples including biomarker-negative patients. Conclusion: With the largest data set so far, we underline the suitability of miR-371a, miR-372, miR-367 and miR-302d in serum and CSF for diagnosis of iGCT, particularly in biomarker-negative germinoma. Diagnosis of iGCT by miRNA analysis is a feasible and valid approach, particularly as serum can be readily obtained by a less invasive procedure. MiRNA analysis may discriminate iGCT from other tumors with similar radiological findings and may allow to monitor response to therapy as well as early relapse during follow-up. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
232. A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
- Author
-
Burris HA, Berlin J, Arkenau T, Cote GM, Lolkema MP, Ferrer-Playan J, Kalapur A, Bolleddula J, Locatelli G, Goddemeier T, Gounaris I, and de Bono J
- Subjects
- Humans, Animals, Dogs, Rats, Carboplatin adverse effects, Protein Kinase Inhibitors, Biomarkers, Bilirubin, Maximum Tolerated Dose, Ataxia Telangiectasia Mutated Proteins metabolism, Neoplasms genetics
- Abstract
Background: Gartisertib is an oral inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), a key kinase of the DNA damage response. We aimed to determine the safety and tolerability of gartisertib ± carboplatin in patients with advanced solid tumours., Methods: This phase I open-label, multicenter, first-in-human study comprised four gartisertib cohorts: A (dose escalation [DE]; Q2W); A2 (DE; QD/BID); B1 (DE+carboplatin); and C (biomarker-selected patients)., Results: Overall, 97 patients were enroled into cohorts A (n = 42), A2 (n = 26), B1 (n = 16) and C (n = 13). The maximum tolerated dose and recommended phase II dose (RP2D) were not declared for cohorts A or B1. In cohort A2, the RP2D for gartisertib was determined as 250 mg QD. Gartisertib was generally well-tolerated; however, unexpected increased blood bilirubin in all study cohorts precluded further DE. Investigations showed that gartisertib and its metabolite M26 inhibit UGT1A1-mediated bilirubin glucuronidation in human but not dog or rat liver microsomes. Prolonged partial response (n = 1 [cohort B1]) and stable disease >6 months (n = 3) did not appear to be associated with biomarker status. Exposure generally increased dose-dependently without accumulation., Conclusion: Gartisertib was generally well-tolerated at lower doses; however, unexpected liver toxicity prevented further DE, potentially limiting antitumour activity. Gartisertib development was subsequently discontinued., Clinicaltrials: GOV: NCT02278250., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
233. Predictors of the development of febrile neutropenia in chemotherapy for advanced germ cell tumors.
- Author
-
Kobayashi K and Kishida T
- Subjects
- Humans, Adult, Retrospective Studies, Granulocyte Colony-Stimulating Factor therapeutic use, Granulocyte Colony-Stimulating Factor adverse effects, Risk Factors, Antineoplastic Combined Chemotherapy Protocols adverse effects, Neoplasms, Febrile Neutropenia chemically induced, Febrile Neutropenia epidemiology, Febrile Neutropenia prevention & control
- Abstract
Objectives: To identify the predictive factors for the development of febrile neutropenia (FN) in the course of chemotherapy for patients with germ cell tumors., Methods: From January 2005 to December 2018, 80 patients were treated with induction chemotherapy for advanced germ cell tumors at Kanagawa Cancer Center Hospital, Japan. Of these, we retrospectively analyzed 267 cycles of chemotherapy. The incidence of FN was used as the objective variable. As predictive factors, we analyzed age, international germ cell consensus classification (IGCCC), laboratory data at the start of chemotherapy in each cycle, length of the largest metastatic lesion, number of cycles, and prophylactic use of granulocyte colony stimulating factor (G-CSF)., Results: We finally analyzed 267 cycles in 78 patients. The median age was 36 years (15-64). There was a total of 267 cycles. FN occurred in 40 cycles (15%) in 31 patients (40%). The first cycle was accompanied by a significantly higher FN than the subsequent cycles (p < 0.001). The univariate analysis identified age ≧36 years (p = 0.001), creatinine clearance (CCr) <70 (p < 0.001), serum albumin <3.3 (p = 0.002), maximum tumor diameter ≧60 mm (p = 0.036), and first cycle as significant risk factors. The multivariate analysis identified age, CCr, and first cycle as independent predictive factors of FN development., Conclusion: We identified older age, renal dysfunction, and first cycle of chemotherapy as predictive factors for FN. No statistically significant difference was shown in the usage of prophylactic G-CSF. Special attention should be given to FN in patients with high-risk factors., (© 2023 The Japanese Urological Association.)
- Published
- 2024
- Full Text
- View/download PDF
234. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
- Author
-
Che, Yuxuan, Liu, Yang, Yao, Yixin, Hill, Holly A., Li, Yijing, Cai, Qingsong, Yan, Fangfang, Jain, Preetesh, Wang, Wei, Rui, Lixin, and Wang, Michael
- Subjects
MANTLE cell lymphoma ,VON Hippel-Lindau disease ,SOMATIC mutation ,AUTOMATED teller machines ,CELLULAR therapy ,SUPPRESSOR mutation - Abstract
Constant challenges for the treatment of mantle cell lymphoma (MCL) remain to be recurrent relapses and therapy resistance, especially in patients harboring somatic mutations in the tumor suppressors ATM and TP53, which are accumulated as therapy resistance emerges and the disease progresses, consistent with our OncoPrint results that ATM and TP53 alterations were most frequent in relapsed/refractory (R/R) MCL. We demonstrated that protein arginine methyltransferase-5 (PRMT5) was upregulated in R/R MCL, which predicted a poor prognosis. PRMT5 inhibitors displayed profound antitumor effects in the mouse models of MCL with mutated ATM and/or TP53, or refractory to CD19-targeted CAR T-cell therapy. Genetic knockout of PRMT5 robustly inhibited tumor growth in vivo. Co-targeting PRMT5, and ATR or CDK4 by using their inhibitors showed synergistic antitumor effects both in vitro and in vivo. Our results have provided a rational combination therapeutic strategy targeting multiple PRMT5-coordinated tumor-promoting processes for the treatment of R/R MCL with high mutation burdens. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
235. Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?
- Author
-
Pozas, Javier, Álvarez Rodríguez, Sara, Fernández, Víctor Albarrán, Burgos, Javier, Santoni, Matteo, Manneh Kopp, Ray, Molina-Cerrillo, Javier, and Alonso-Gordoa, Teresa
- Subjects
ANTIANDROGENS ,IMMUNE checkpoint inhibitors ,CELLULAR signal transduction ,SURVIVAL analysis (Biometry) ,ANDROGEN receptors ,DRUG resistance in cancer cells - Abstract
Simple Summary: Prostate cancer progression is mainly driven by the androgen receptor (AR) signaling pathway and its inhibition has been the cornerstone in the treatment of patients harboring this disease. However, during the course of prostate cancer, various resistance mechanisms have been defined as responsible for tumor progression and the lack of response to current antiandrogen drugs. These resistance mechanisms act directly over the AR signaling pathway, but also over other bypassing pathways that could potentially be targetable. Therefore, the improvement in the molecular knowledge of prostate cancer progression and the development of new active therapies may overcome the current limits in prolonging the survival of patients with prostate cancer. The androgen signaling pathway is the cornerstone in the treatment of high risk or advanced prostate cancer patients. However, in recent years, different mechanisms of resistance have been defined in this field, limiting the efficacy of the currently approved antiandrogen drugs. Different therapeutic approaches are under research to assess the role of combination therapies against escape signaling pathways or the development of novel antiandrogen drugs to try to solve the primary or acquired resistance against androgen dependent or independent pathways. The present review aims to summarize the current state of androgen inhibition in the therapeutic algorithm of patients with advanced prostate cancer and the mechanisms of resistance to those available drugs. In addition, this review conducted a comprehensive overview of the main present and future research approaches in the field of androgen receptor inhibition to overcome these resistances and the potential new drugs under research coming into this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
236. Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma.
- Author
-
Waninger, Jessica J., Fecher, Leslie A., Lao, Christopher, Yentz, Sarah, Green, Michael D., and Demirci, Hakan
- Subjects
MELANOMA prognosis ,IMMUNE checkpoint inhibitors ,MELANOMA ,UVEA cancer ,MONOCLONAL antibodies ,CANCER patients ,TREATMENT effectiveness ,NEUTROPHIL lymphocyte ratio ,DESCRIPTIVE statistics ,TUMOR markers ,PROGRESSION-free survival ,EVALUATION - Abstract
Simple Summary: Uveal melanoma is a rare form of melanoma but is the most common tumor in the eye. Despite having effective treatments for the initial tumor, many patients experience the spread of their cancer to distant body sites. There is no uniform way of treating metastatic disease, but physicians often use therapies that harness the patient's immune system because these same treatments have been very effective in other types of melanoma. Not all patients respond to this therapy though, and some develop toxicity related to the treatment. The goal of this paper was to identify features or blood markers that may help determine response to treatment early. Specifically, we analyzed a molecule called lactate dehydrogenase (LDH) and the ratio of different white blood cells at the start of therapy and 2 months after treatment was started. We found that these non-invasive blood markers could be useful in determining which patients are responding to treatment. Background: There is no standardized treatment for metastatic uveal melanoma (MUM) but immune checkpoint inhibitors (ICI) are increasingly used. While ICI has transformed the survival of metastatic cutaneous melanoma, MUM patients do not equally benefit. Factors known to affect ICI response include the hematologic markers, lactate dehydrogenase (LDH) and neutrophil:lymphocyte ratio (NLR). We evaluated the prognostic value of LDH and NLR at the start of ICI and on treatment in MUM. Methods: MUM patients were treated between August 2006 and May 2022 with combination ipilimumab/nivolumab or ipilimumab/nivolumab/pembrolizumab single-agent therapy. Univariable (UVA) and multivariable (MVA) analyses were used to assess the prognostic value of predefined baseline factors on progression-free (PFS) and overall survival (OS). Results: In forty-six patients with MUM treated with ICI, elevated baseline and on-treatment LDH was prognostic for OS (start of ICI, HR (95% CI): 3.6 (1.9–7.0), p < 0.01; on-treatment, HR (95% CI): 3.7 (1.6–8.8), p < 0.01) and PFS (start of ICI, (HR (95% CI): 2.8 (1.5–5.4), p < 0.0001); on-treatment LDH (HR (95% CI): 2.2 (1.1–4.3), p < 0.01). On-treatment NLR was prognostic for PFS (HR (95% CI): 1.9 (1.0–3.9), p < 0.01). On-treatment LDH remained an important contributor to survival on MVA (OS: HR (95% CI): 1.001 (1.00–1.002), p < 0.05); PFS: HR (95% CI): 1.001 (1.00–1.002), p < 0.01). Conclusions: This study demonstrates that LDH and NLR could be useful in the prognostication of MUM patients treated with ICI. Additional studies are needed to confirm the importance of these and other prognostic biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
237. Late mortality reduction among survivors of germ cell tumors in childhood and adolescence in Europe: A report from the PanCareSurFup cohort.
- Author
-
Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Byrne, Julianne, Grabow, Desiree, Reulen, Raoul C., Calaminus, Gabriele, and Terenziani, Monica
- Published
- 2022
- Full Text
- View/download PDF
238. Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis.
- Author
-
Law, Jeanna Wallenta, Campbell, Alicyn, Weller, Colin, Johanson, Colden, Broome, Ronda, Piault, Elisabeth, Izano, Monika, Schrag, Andrew, Tran, Mary, Brown, Thomas D., and Kaplan, Henry G.
- Abstract
Purpose: Using real-world data, interstitial lung disease (ILD) prevalence before and after HER2-directed therapy was estimated. Potential ILD risk factors in patients receiving HER2-directed therapy for metastatic breast cancer (mBC) were evaluated. Methods: Adults with HER2-directed therapy for mBC initiated between September 25, 1998, and February 22, 2020 were, included. ILD was defined broadly as one or more of 64 lung conditions. Patients were followed until incident ILD, death, last contact, or study end. Results: In total, 533 patients were identified with median age at mBC of 57, 51% had de novo mBC, 43% were ever smokers, 30% had lung metastases, 9% had thoracic radiation, 6% had chronic obstructive pulmonary disease, and 16% had prevalent ILD. ILD cumulative incidence at one year was 9% (95% CI 6%, 12%), with a median follow-up of 23 months. Smoking (HR 2.2, 95% CI 1.1, 4.8) and Black/African-American race (HR 3.4, 95% CI 1.6, 7.5) were significantly associated with ILD; HRs for preexisting lung conditions (HR 1.8, 95% CI 0.9, 3.8) and thoracic radiation (HR 2.3, 95% CI 0.8, 7.1) were not statistically significant. Prevalent ILD was associated with 13-fold greater occurrence of incident ILD. 85% of patients with prevalent or incident ILD were symptomatic. Conclusions: This real-world population of patients with mBC had a high prevalence of ILD prior to HER2-directed therapy, reflecting the multifactorial causation of interstitial lung changes. The cumulative incidence of ILD in patients receiving HER2-directed therapy for mBC augments prior reports. Symptomatic presentation suggests an opportunity for early intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
239. Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review.
- Author
-
Ruf, Christian G., Schmidt, Stefanie, Kliesch, Sabine, Oing, Christoph, Pfister, David, Busch, Jonas, Heinzelbecker, Julia, Winter, Christian, Zengerling, Friedemann, Albers, Peter, Oechsle, Karin, Krege, Susanne, Lackner, Julia, and Dieckmann, Klaus-Peter
- Subjects
OVERALL survival ,SEMINOMA ,GERM cells ,SURVIVAL rate ,LYMPHADENECTOMY ,WATCHFUL waiting - Abstract
Purpose: Testicular germ cell tumours (GCTs) represent the most common malignancy in young adult males with two thirds of all cases presenting with clinical stage I (CSI). Active surveillance is the management modality mostly favoured by current guidelines. This systematic review assesses the treatment results in CSI patients concerning recurrence rate and overall survival in non-seminoma (NS) and pure seminoma (SE) resulting from surveillance in comparison to adjuvant strategies. Methods/systematic review: We performed a systematic literature review confining the search to most recent studies published 2010–2021 that reported direct comparisons of surveillance to adjuvant management. We searched Medline and the Cochrane Library with additional hand-searching of reference lists to identify relevant studies. Data extraction and quality assessment of included studies were performed with stratification for histology (NS vs. SE) and treatment modalities. The results were tabulated and evaluated with descriptive statistical methods. Results: Thirty-four studies met the inclusion criteria. In NS patients relapse rates were 12 to 37%, 0 to 10%, and 0 to 11.8% for surveillance, chemotherapy and for retroperitoneal lymph node dissection (RPLND) while overall survival rates were 90.7−100%, 91.7−100%, and 97−99.1%, respectively. In SE CSI, relapse rates were 0−22.3%, 0−5%, and 0−12.5% for surveillance, radiotherapy, chemotherapy, while overall survival rates were 84.1−98.7%, 83.5−100%, and 92.3−100%, respectively. Conclusion: In both histologic subgroups, active surveillance offers almost identical overall survival as adjuvant management strategies, however, at the expense of higher relapse rates. Each of the management strategies in CSI GCT patients have specific merits and shared-decision-making is advised to tailor treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
240. Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer.
- Author
-
Venetis, Konstantinos, Pepe, Francesco, Munzone, Elisabetta, Sajjadi, Elham, Russo, Gianluca, Pisapia, Pasquale, Ivanova, Mariia, Bonizzi, Giuseppina, Vacirca, Davide, Rappa, Alessandra, Ranghiero, Alberto, Taormina, Sergio Vincenzo, Viale, Giuseppe, Troncone, Giancarlo, Barberis, Massimo, Guerini-Rocco, Elena, Malapelle, Umberto, and Fusco, Nicola
- Subjects
NUCLEOTIDE sequencing ,REVERSE transcriptase polymerase chain reaction ,BREAST cancer ,SOMATIC mutation ,HORMONE receptors ,BREAST - Abstract
Somatic mutations in PIK3CA are present in ~40% breast cancers (BC); their detection in hormone receptor (HR)+/HER2− tumors allows for selecting patients with advanced disease eligible for PIK3CA targeting with alpelisib. The choice of what type of PIK3CA testing approach to adopt and which tissue sample to analyze is a new task in breast pathology. In this methodological study, we sought to assess the performance of next-generation sequencing (NGS) and RT-PCR for PIK3CA testing on archival formalin-fixed paraffin-embedded (FFPE) primary tumors and corresponding metastases. Sixteen HR+/HER2− BC with known PIK3CA-mutated status (ex. 7, 9, and 20) on metastatic samples by means of amplicon-based targeted NGS were selected, and n = 13 of these samples were re-tested with a commercially available CE-IVD RT-PCR assay. All available primary tumors (n = 8) were tested with both methods. NGS detected mutations in all samples, while RT-PCR in n = 2 sample-pairs and overall, in n = 5/8 (62.5%) primary tumors and 7/13 (53.8%) metastases (κ = 0.09; 95% CI, −0.69–0.87). Slight agreement (κ = 0; 95% CI, −0.59–0.59) was observed between NGS and RT-PCR, with the former being generally more sensitive in cases with low DNA quality and quantity. Post hoc visual inspection of the RT-PCR data increased the concordance to 76.9%. Targeted NGS offers reliable and robust PIK3CA testing on both tumor and metastasis FFPE samples; the accuracy of RT-PCR depends on the DNA quantity and quality. In HR+/HER2− BC, both the selection of the PIK3CA testing strategy of FFPE tissues and which sample to analyze should consider several technical parameters and should be tailored for each case. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
241. Quantitation of the ataxia‐telangiectasia‐mutated and Rad3‐related inhibitor elimusertib (BAY‐1895344) in human plasma using LC–MS/MS.
- Author
-
Kiesel, Brian F., Parise, Robert A., Krishnamurthy, Anuradha, Gore, Steven, and Beumer, Jan H.
- Abstract
Ataxia‐telangiectasia‐mutated and Rad3‐related (ATR) is master regulator of the DNA‐damage response that, through multiple mechanisms, can promote cancer cell survival in response to replication stress from sources, including chemotherapy and radiation. Elimusertib (BAY‐1895344) is an orally available small‐molecule ATR inhibitor currently in preclinical and clinical development for cancer treatment. To support these studies and define elimusertib pharmacokinetics, we developed a HPLC–MS method for its quantitation. A 50‐μL volume of plasma was subjected to acetonitrile protein precipitation and then chromatographic separation using a Phenomenex Polar‐RP column (2 × 50 mm, 4 μm) and a gradient mobile phase consisting of 0.1% formic acid in acetonitrile and water during a 7‐min run time. Mass spectrometric detection was achieved using a SCIEX 4000 triple‐stage mass spectrometer with electrospray positive‐mode ionization. With a stable isotopic internal standard, the assay was linear from 30 to 5000 ng/mL and proved to be both accurate (93.5–108.2%) and precise (<6.3% coefficient of variation) fulfilling criteria from the Food and Drug Administration guidance on bioanalytical method validation. This LC–MS/MS assay will support several ongoing clinical studies by defining elimusertib pharmacokinetics. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
242. Sprachtransgressionen: Interlingualität und Multimodalität im klassisch-romantischen Diskurskontinuum: ein Blick über das Nebelmeer.
- Author
-
Bär, Jochen A.
- Abstract
Copyright of Lexicographica is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
243. Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer.
- Author
-
Zhang, Jing, Chan, Doug W., and Lin, Shiaw-Yih
- Subjects
DNA replication ,BREAST cancer ,DNA repair ,DRUG toxicity ,PATIENT selection - Abstract
Proliferating cells rely on DNA replication to ensure accurate genome duplication. Cancer cells, including breast cancer cells, exhibit elevated replication stress (RS) due to the uncontrolled oncogenic activation, loss of key tumor suppressors, and defects in the DNA repair machinery. This intrinsic vulnerability provides a great opportunity for therapeutic exploitation. An increasing number of drug candidates targeting RS in breast cancer are demonstrating promising efficacy in preclinical and early clinical trials. However, unresolved challenges lie in balancing the toxicity of these drugs while maintaining clinical efficacy. Furthermore, biomarkers of RS are urgently required to guide patient selection. In this review, we introduce the concept of targeting RS, detail the current therapies that target RS, and highlight the integration of RS with immunotherapies for breast cancer treatment. Additionally, we discuss the potential biomarkers to optimizing the efficacy of these therapies. Together, the continuous advances in our knowledge of targeting RS would benefit more patients with breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
244. Resistance to DNA repair inhibitors in cancer.
- Author
-
Baxter, Joseph S., Zatreanu, Diana, Pettitt, Stephen J., and Lord, Christopher J.
- Published
- 2022
- Full Text
- View/download PDF
245. Author Index.
- Subjects
AUTHORS ,CHIA - Published
- 2022
- Full Text
- View/download PDF
246. Association Between Adrenal-Restrictive HSD3B1 Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer.
- Author
-
McManus, Jeffrey M, Vargas, Roberto, Bazeley, Peter S, Schumacher, Fredrick R, and Sharifi, Nima
- Subjects
HORMONES ,BREAST cancer ,ENDOMETRIAL cancer - Abstract
Background The germline variant rs1047303 (HSD3B1 [1245A/C]), restricting or enabling production of potent androgens and estrogens from adrenal precursors, affects outcomes of castration-resistant prostate cancer and is associated with estrogen receptor positivity in postmenopausal breast cancer. Like breast cancer, endometrial cancer is another malignancy with hormone-dependent and hormone-independent subtypes. We hypothesized that adrenal-restrictive HSD3B1 genotype would associate with hormone-independent cancer subtypes. Methods We employed a previously described classification of tumors in The Cancer Genome Atlas into genomic clusters. We determined HSD3B1 genotype frequencies by endometrial cancer genomic cluster and calculated the odds per adrenal-restrictive A allele for the largely hormone-independent copy-number (CN) high subtype vs other subtypes. An equivalent analysis was performed for the genomically similar, hormone-independent basal breast cancer subtype. Last, we performed survival analyses for UK Biobank participants with endometrial cancer by HSD3B1 genotype. All statistical tests were 2-sided. Results The adrenal-restrictive HSD3B1 (1245A) allele was associated with the CN-high endometrial cancer subtype (odds ratio [OR] = 1.63, 95% confidence interval [CI] = 1.14 to 2.32; P = .007). Similarly, HSD3B1 (1245A) was associated with the basal breast cancer subtype (OR = 1.54, 95% CI = 1.13 to 2.08; P = .006). In the UK Biobank, endometrial cancer patients homozygous for HSD3B1 (1245A) had worse overall (hazard ratio [HR] = 1.39, 95% CI = 1.16 to 1.68; P < .001) and cancer-specific (HR = 1.39, 95% CI = 1.14 to 1.70; P = .001) survival, consistent with the A allele being enriched in the more aggressive CN-high subtype. Conclusions These findings suggest roles for adrenal-restrictive vs adrenal-permissive steroidogenesis, by way of rs1047303 genotype, in the development of and/or outcomes from at least 3 commonly hormone-associated types of cancer: prostate, breast, and endometrial. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
247. Targeting the DNA damage response in pediatric malignancies.
- Author
-
Gedminas, Jenna M and Laetsch, Theodore W
- Abstract
Introduction: High levels of DNA damage and mutations in DNA damage response genes create a high reliance on DNA damage repair in various tumors. This creates a vulnerability for new cancer therapies. Although there is extensive data for the use of these agents in adult tumors, the evaluation of these compounds in the pediatric population remains in the early stages.Areas Covered: In this review, we discuss the role of the DNA damage response as a therapeutic vulnerability in pediatric malignancies, provide a summary of clinical data for the use of DNA damage response inhibitors in cancer, and review how these compounds can be extended to the pediatric population.Expert Opinion: A number of pediatric cancers rely on robust DNA damage repair to maintain cell viability. This provides a therapeutic vulnerability in cancer cells resistant to other traditional therapies. Unfortunately, although clinical evaluation of inhibitors of various components of the DNA damage response has been done in adults, pediatric data remain limited. Further studies are needed to evaluate the efficacy of these compounds in the pediatric population. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
248. Testicular tumors in the “elderly” population.
- Author
-
Secondino, Simona, Rosti, Giovanni, Tralongo, Antonino C., Nolè, Franco, Alaimo, Domiziana, Carminati, Ornella, John Naspro, Richard Lawrence, and Pedrazzoli, Paolo
- Subjects
TESTICULAR cancer ,GERM cell tumors ,OLDER people ,PINEAL gland ,TUMORS ,SEMINOMA - Abstract
Germ cell tumors arise in childhood but peak at around 30 years of age. They are the most common cancers in males under the age of 35. Over 95% arise in the testes while a minority originate in extragonadal sites such as the anterior mediastinum, or mainly in childhood the pineal gland or the sacrococcygeal area. These tumors show an extraordinary sensitivity to chemotherapy (and for seminoma, also to radiation) and cure rates are relatively high even in second or subsequent relapses. Very few data are present in the literature regarding patients diagnosed after 50 years and no specific trials have been conducted in this setting. Nearly all patients reported in the literature had testicular cancers, with occasional reports of extragonadal tumors. Despite the fact that > 50 years may be considered an “elderly” population, these patients are treated with the same cisplatin containing combinations as their younger counterparts with consequent higher toxicity. In this review we will present epidemiological and clinical data from this rare population of patients with testicular cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
249. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
- Author
-
Ngoi, Natalie Y.L., Westin, Shannon N., and Yap, Timothy A.
- Published
- 2022
- Full Text
- View/download PDF
250. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien: Abstracts.
- Subjects
- VIENNA (Austria)
- Abstract
na [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.